{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:23:45Z","timestamp":1793071425464,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ejca.2020.11.027","type":"journal-article","created":{"date-parts":[[2020,12,26]],"date-time":"2020-12-26T05:26:01Z","timestamp":1608960361000},"page":"215-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["The association between immune checkpoint or BRAF\/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma"],"prefix":"10.1016","volume":"144","author":[{"given":"Florentia","family":"Dimitriou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Urner-Bloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Eggenschwiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Mitsakakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Mangana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Urner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.11.027_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.027_bib2","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.11.027_bib3","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.11.027_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.027_bib5","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.11.027_bib6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","article-title":"Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib","volume":"36","author":"Long","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.027_bib7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.11.027_bib8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2020.11.027_bib9","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.11.027_bib10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.11.027_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.11.027_bib12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2020.11.027_bib13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review","volume":"17","author":"Abdel-Rahman","year":"2017","journal-title":"Expet Rev Anticancer Ther"},{"key":"10.1016\/j.ejca.2020.11.027_bib14","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.ejca.2020.11.027_bib15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ajo.2019.02.012","article-title":"Prevalence and clinical patterns of ocular complications associated with anti-PD-1\/PD-L1 anticancer immunotherapy","volume":"202","author":"Bitton","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ejca.2020.11.027_bib16","first-page":"1","article-title":"Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition","author":"Sun","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"10.1016\/j.ejca.2020.11.027_bib17","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ophtha.2019.01.031","article-title":"Ophthalmic immune-related adverse events of immunotherapy: a single-site case series","volume":"126","author":"Kim","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejca.2020.11.027_bib18","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ajo.2014.07.003","article-title":"Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib","volume":"158","author":"Choe","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ejca.2020.11.027_bib19","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/annonc\/mdw100","article-title":"Ocular toxicities of MEK inhibitors and other targeted therapies","volume":"27","author":"Stjepanovic","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.11.027_bib20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000446845","article-title":"Risk of ophthalmic adverse effects in patients treated with MEK inhibitors: a systematic review and meta-analysis","volume":"57","author":"Alves","year":"2017","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.ejca.2020.11.027_bib21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejca.2016.06.018","article-title":"MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: long-term ophthalmic effects","volume":"65","author":"Urner-Bloch","year":"2016","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.11.027_bib22","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1055\/s-0042-102668","article-title":"Intraocular inflammation associated with new therapies for cutaneous melanoma - case series and review","volume":"233","author":"Fierz","year":"2016","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.ejca.2020.11.027_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00417-017-3835-2","article-title":"Checkpoint inhibitor-induced uveitis: a case series","volume":"256","author":"Conrady","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ejca.2020.11.027_bib24","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00002371-200411000-00008","article-title":"Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis","volume":"27","author":"Robinson","year":"2004","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2020.11.027_bib25","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/CMR.0000000000000505","article-title":"Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma","volume":"28","author":"Diamantopoulos","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2020.11.027_bib26","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.ophtha.2016.08.037","article-title":"Big data and uveitis","volume":"123","author":"Lee","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejca.2020.11.027_bib27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature working G. Standardization of uveitis\u00a0nomenclature for reporting clinical data. Results of the First international workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ejca.2020.11.027_bib28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ophtha.2003.06.014","article-title":"Incidence and prevalence of uveitis in Northern California; the Northern California epidemiology of uveitis study","volume":"111","author":"Gritz","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejca.2020.11.027_bib29","article-title":"rjags: Bayesian graphical models using MCMC","volume":"3","author":"Plummer","year":"2013","journal-title":"R package version"},{"key":"10.1016\/j.ejca.2020.11.027_bib30","series-title":"Proceedings of the 3rd international workshop on distributed statistical computing","article-title":"A program for analysis of Bayesian graphical models using Gibbs sampling","author":"Plummer","year":"2003"},{"key":"10.1016\/j.ejca.2020.11.027_bib31","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.preteyeres.2011.06.005","article-title":"Understanding uveitis: the impact of research on visual outcomes","volume":"30","author":"de Smet","year":"2011","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ejca.2020.11.027_bib32","doi-asserted-by":"crossref","first-page":"102454","DOI":"10.1016\/j.jaut.2020.102454","article-title":"Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's\u00a0pharmacovigilance database","author":"Anquetil","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ejca.2020.11.027_bib33","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaophthalmol.2013.4237","article-title":"Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study","volume":"131","author":"Acharya","year":"2013","journal-title":"JAMA ophthalmology"},{"key":"10.1016\/j.ejca.2020.11.027_bib34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1600-0420.1995.tb00040.x","article-title":"Epidemiology of endogenous uveitis in\u00a0south-western Finland","volume":"73","author":"Saari","year":"1995","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.ejca.2020.11.027_bib35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/09273949409057073","article-title":"Epidemiology of uveitis in Switzerland","volume":"2","author":"Tran","year":"1994","journal-title":"Ocul Immunol Inflamm"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:31:40Z","timestamp":1760733100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920313642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":35,"alternative-id":["S0959804920313642"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.027","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The association between immune checkpoint or BRAF\/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}